Richard Heier

Richard Heier has worked for several companies since 1984. Richard began their career at Legacy Upjohn, Pharmacia & Upjohn, Pharmacia as a Chemist, where they were a key member on teams that have been successful in bringing new drug entities to the clinical trial phase. Richard also synthesized the primary metabolite of Irinotecan and enhanced the effectiveness of infectious disease drugs by synthesizing compounds targeting the inhibition of HCV viral enzymes. In 2003, they joined Pfizer Pharmaceuticals as a Principal Scientist, where they were involved in novel drug target design and synthesis of compounds targeting kinases for the treatment of inflammation, allergy, and respiration. In 2010, they joined Washington University in St. Louis as a Staff Scientist in the Division of Pulmonary and Critical Care Medicine, where they utilized genome-guided screening methods to identify new drugs for the treatment of respiratory diseases. In 2014, they joined St. Louis University School of Medicine as a Research Scientist, where they were involved in the design and synthesis of small molecules for the treatment of rare and neglected diseases. Lastly, in 2017, they joined Confluence Discovery Technologies as a Project Manager and Principal Scientist.

Richard Heier attended the University of Illinois Urbana-Champaign, where they earned a Bachelor of Science degree in Chemistry.